A Case of Coexistence of Bone Marrow-involved Refractory Marginal Zone B-Cell Lymphoma and Therapy-related Myelodysplastic Syndrome
Laboratory Medicine Online
;
: 98-101, 2016.
Article
in English
| WPRIM
| ID: wpr-16398
ABSTRACT
Recent advances in chemotherapy have led to increased survival rates for patients with hematologic malignancies. However, standard chemotherapies, including alkylating agents for non-Hodgkin lymphoma, could induce therapy-related myeloid neoplasms (t-MNs), a group of disorders categorized by the World Health Organization in 2008. Here, we report a case of coexistence of bone marrow (BM)-involved refractory marginal zone B-cell lymphoma (MZL) and therapy-related myelodysplastic syndrome (t-MDS). Simultaneous presence of refractory lymphoma and t-MN in the BM is rare, and this is the first report in Korea. The patient received allogeneic hematopoietic stem cell transplantation (HSCT) to cure both the MZL and t-MDS. Since the HSCT, he has been stable for 21 months without any evidence of recurrence.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
World Health Organization
/
Bone Marrow
/
Myelodysplastic Syndromes
/
Lymphoma, Non-Hodgkin
/
Survival Rate
/
Lymphoma, B-Cell, Marginal Zone
/
Hematopoietic Stem Cell Transplantation
/
Hematologic Neoplasms
/
Drug Therapy
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Laboratory Medicine Online
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS